bluebird bio, TC BioPharm announce strategic collaboration and license agreement
bluebird bio and Scottish immunotherapy company TC BioPharm announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm's lead CAR-engineered gamma delta T cell program into clinical trials as well as on additional hematologic and solid tumor targets. Under the terms of the agreement, bluebird bio and TCB will collaborate to discover and develop CAR-engineered gamma delta T cells for cancer targets and indications. TCB is responsible for development of all targets through Phase 1/2, at which point bluebird has the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis. Financial terms of the agreement include a $16M upfront payment and subsequent potential R&D and commercial milestone payments. TCB is also eligible to receive undisclosed tiered royalties on product sales.